SCHEMBL3745489

SCHEMBL3745489

NCc1ccccc1C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.42
NAAA Q02083 1/20 0.42
NUDT1 P36639 1/20 0.40
BACE1 P56817 1/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
OPRL1 P41146 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PNMT P11086 1/20 0.39
PTGS2 P35354 1/20 0.38
DPP4 P27487 1/20 0.36
NOS1 P29475 1/20 0.36
HTR2A P28223 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
TDO2 P48775 1/20 0.35
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL13268822 0.98 PTGDR2 (0.41) PTGDR2NAAANUDT1BACE1OPRM1
SCHEMBL3750890 0.98 SLC6A2 (0.40) PTGDR2NAAANUDT1BACE1OPRM1
Hydrochloric Acid SCHEMBL3756190 0.96 SLC6A2 (0.39) PTGDR2NAAANUDT1BACE1OPRM1
SCHEMBL12954599 0.94 PNMT (0.40) PTGDR2NAAAOPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL15921931 0.92 SLC6A2 (0.39) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL5450499 0.90 PNMT (0.43) OPRM1OPRD1OPRK1OPRL1SLC6A2
Hydrochloric Acid SCHEMBL18336575 0.88 PNMT (0.41) OPRM1OPRD1OPRK1OPRL1SLC6A2
SCHEMBL3844188 0.85 NUDT1 (0.49) PTGDR2NAAANUDT1BACE1SLC6A2
SCHEMBL20840816 0.83 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3
SCHEMBL3842826 0.82 HTR2A (0.49) PTGDR2NAAANUDT1BACE1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100379719-C Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2008-04-09 CN claimed
US-20070105785-A1 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-10 US claimed
US-7125848-B2 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2006-10-24 US claimed
US-7041704-B2 Methods of treating gastrointestinal tract disorders using sodium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1596844-A2 USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS Dynogen Pharmaceuticals Inc. (US) 2005-11-23 EP claimed
EP-1589959-A2 METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS Dynogen Pharmaceuticals Inc. (US) 2005-11-02 EP claimed
US-20050203190-A1 Methods of treating gastrointestinal tract disorders using sodium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2005-09-15 US claimed
US-20050107353-A1 Methods of treating lower urinary tract disorders using losigamone DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-19 US claimed
US-20050026835-A1 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2005-02-03 US claimed
WO-2005000285-A2 METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS DYNOGEN PHARMACEUTICALS, INC. (US) 2005-01-06 WO claimed
US-20040248979-A1 Method of treating lower urinary tract disorders DYNOGEN PHARMACEUTICALS, INC. 2004-12-09 US claimed
EP-1246793-B1 SUBSTITUTED AMINOMETHYL-PHENYL-CYCLOHEXANE DERIVATIVES GRUENENTHAL GMBH (DE) 2004-11-10 EP claimed
US-20040213842-A1 Methods of treating gastrointestinal tract disorders using sodium channel modulators DYNOGEN PHARMACEUTICALS, INC. 2004-10-28 US claimed
US-20040209960-A1 Methods of treating lower urinary tract disorders using sodium channell modulators DYNOGEN PHARMACEUTICALS, INC. 2004-10-21 US claimed
WO-2004066990-A2 METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS DYNOGEN PHARMACEUTICALS, INC. (US) 2004-08-12 WO claimed
WO-2004066987-A2 USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS DYNOGEN PHARMACEUTICALS, INC. (US) 2004-08-12 WO claimed
US-6673794-B2 ANALGESICS, INCOTINENCE, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS GRUENENTHAL GMBH (DE) 2004-01-06 US claimed
CN-1437576-A Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2003-08-20 CN claimed
US-20030069288-A1 Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENETHAL GMBH (DE) 2003-04-10 US claimed
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2019-01-08 US disclosed
EP-2766352-B1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIV HEALTH NETWORK UHN (CA) 2018-06-06 EP disclosed
EP-2657214-B1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL MITSUBISHI GAS CHEMICAL CO (JP) 2017-02-15 EP disclosed
CN-103298772-B Method for producing aromatic alcohol or heterocyclic aromatic alcohol MITSUBISHI GAS CHEMICAL CO 2015-06-24 CN disclosed
US-8993774-B2 Process for production of aromatic alcohol or heterocyclic aromatic alcohol MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2015-03-31 US disclosed
EP-2766352-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME University Health Network (UHN) (CA) 2014-08-20 EP disclosed
US-20130303775-A1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2013-11-14 US disclosed
EP-2657214-A1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL Mitsubishi Gas Chemical Company, Inc. (JP) 2013-10-30 EP disclosed
CN-103298772-A Method for producing aromatic alcohol or heterocyclic aromatic alcohol MITSUBISHI GAS CHEMICAL CO 2013-09-11 CN disclosed
WO-2013053051-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2013-04-18 WO disclosed
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2013-02-21 US disclosed
EP-2511283-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-10-17 EP disclosed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2130820-A1 Antipruritics SHIONOGI & CO., LTD. (JP) 2009-12-09 EP disclosed
EP-1477186-B1 ANTIPRURITICS SHIONOGI & CO (JP) 2009-11-11 EP disclosed
CN-101528690-A Isoindoline derivatives for the treatment of arrhythmias ASTRAZENECA AB (SE) 2009-09-09 CN disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-20090099143-A1 TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS LAGU BHARAT 2009-04-16 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-7452997-B2 Tetrahydro-indazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-18 US disclosed
US-7420053-B2 2-imino-1,3-thiazine derivatives SHIONOGI & CO., LTD. (JP) 2008-09-02 US disclosed
EP-1375489-B1 MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE SHIONOGI & CO (JP) 2008-08-20 EP disclosed
EP-1219612-B1 2-IMINO-1,3-THIAZINE DERIVATIVES SHIONOGI & CO (JP) 2008-04-23 EP disclosed
CN-100379719-C Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2008-04-09 CN disclosed
CN-100379719-C Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2008-04-09 CN disclosed
CN-100379719-C Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2008-04-09 CN disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed
US-20070105785-A1 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-10 US disclosed
US-20070088020-A1 2-imino-1,3-thiazine derivatives HANASAKI KOJI 2007-04-19 US disclosed
CN-1301981-C Medicinal composition containing 1,3-thiazine derivative SHIONOGI & CO (JP) 2007-02-28 CN disclosed
US-7183275-B2 2-imino-1,3-thiazine derivatives SHIONOGI CO., LTD. (JP) 2007-02-27 US disclosed
EP-1735286-A1 TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-27 EP disclosed
US-7125848-B2 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2006-10-24 US disclosed
US-7041704-B2 Methods of treating gastrointestinal tract disorders using sodium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed
CN-1247553-C 2-imino-1,3-thiazine derivs. SHIONOGI & CO (JP) 2006-03-29 CN disclosed
EP-1596844-A2 USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS Dynogen Pharmaceuticals Inc. (US) 2005-11-23 EP disclosed
EP-1589959-A2 METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS Dynogen Pharmaceuticals Inc. (US) 2005-11-02 EP disclosed
WO-2005095353-A1 TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-10-13 WO disclosed
US-20050228034-A1 Tetrahydro-indazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2005-10-13 US disclosed
US-20050203190-A1 Methods of treating gastrointestinal tract disorders using sodium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2005-09-15 US disclosed
US-6916806-B2 Medicinal composition containing 1,3-thiazine derivative SHIONOGI & CO., LTD. (JP) 2005-07-12 US disclosed
US-20050124617-A1 2-Imino-1,3-thiazine derivatives HANASAKI KOJI (JP) 2005-06-09 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
US-20050107353-A1 Methods of treating lower urinary tract disorders using losigamone DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-19 US disclosed
US-20050101590-A1 Cannabinoid receptor agonists SHIONOGI & CO., LTD. (JP) 2005-05-12 US disclosed
US-20050026835-A1 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators DYNOGEN PHARMACEUTICALS, INC. (US) 2005-02-03 US disclosed
WO-2005000285-A2 METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS DYNOGEN PHARMACEUTICALS, INC. (US) 2005-01-06 WO disclosed
US-20040248979-A1 Method of treating lower urinary tract disorders DYNOGEN PHARMACEUTICALS, INC. 2004-12-09 US disclosed
US-20040248979-A1 Method of treating lower urinary tract disorders DYNOGEN PHARMACEUTICALS, INC. 2004-12-09 US disclosed
EP-1477186-A1 ANTIPRURITICS SHIONOGI & CO., LTD. (JP) 2004-11-17 EP disclosed
US-6818640-B1 BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS SHIONOGI & CO., LTD. (JP) 2004-11-16 US disclosed
EP-1246793-B1 SUBSTITUTED AMINOMETHYL-PHENYL-CYCLOHEXANE DERIVATIVES GRUENENTHAL GMBH (DE) 2004-11-10 EP disclosed
US-20040213842-A1 Methods of treating gastrointestinal tract disorders using sodium channel modulators DYNOGEN PHARMACEUTICALS, INC. 2004-10-28 US disclosed
US-20040209960-A1 Methods of treating lower urinary tract disorders using sodium channell modulators DYNOGEN PHARMACEUTICALS, INC. 2004-10-21 US disclosed
WO-2004066987-A2 USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS DYNOGEN PHARMACEUTICALS, INC. (US) 2004-08-12 WO disclosed
WO-2004066990-A2 METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS DYNOGEN PHARMACEUTICALS, INC. (US) 2004-08-12 WO disclosed
CN-1514831-A Medicinal composition containing 1,3-thiazine derivative ��Ұ����ҩ��ʽ���� 2004-07-21 CN disclosed
US-20040116326-A1 Medicinal composition containing 1,3-thiazine derivative SHIONOGI & CO., LTD. (JP) 2004-06-17 US disclosed
WO-2004005267-A1 HETEROARYL COMPOUNDS USEFUL IN TREATING INFLAMMATORY DISORDERS 2004-01-15 WO disclosed
US-6673794-B2 ANALGESICS, INCOTINENCE, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS GRUENENTHAL GMBH (DE) 2004-01-06 US disclosed
US-6673794-B2 ANALGESICS, INCOTINENCE, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS GRUENENTHAL GMBH (DE) 2004-01-06 US disclosed
US-6673794-B2 ANALGESICS, INCOTINENCE, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS GRUENENTHAL GMBH (DE) 2004-01-06 US disclosed
EP-1375489-A1 MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2004-01-02 EP disclosed
CN-1437576-A Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2003-08-20 CN disclosed
CN-1437576-A Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2003-08-20 CN disclosed
CN-1437576-A Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENENTHAL GMBH (DE) 2003-08-20 CN disclosed
US-20030069288-A1 Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENETHAL GMBH (DE) 2003-04-10 US disclosed
US-20030069288-A1 Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENETHAL GMBH (DE) 2003-04-10 US disclosed
US-20030069288-A1 Substituted aminomethyl-phenyl-cyclohexane derivatives GRUENETHAL GMBH (DE) 2003-04-10 US disclosed
CN-1387519-A 2-imino-1, 3-thiazine derivatives SHIONOGI & CO (JP) 2002-12-25 CN disclosed
EP-1246793-A2 SUBSTITUTED AMINOMETHYL-PHENYL-CYCLOHEXANE DERIVATIVES Grünenthal GmbH (DE) 2002-10-09 EP disclosed
EP-1219612-A1 2-IMINO-1,3-THIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2002-07-03 EP disclosed
WO-2001049654-A3 SUBSTITUTED AMINOMETHYL-PHENYL-CYCLOHEXANE DERIVATIVES GRUENENTHAL GMBH (DE) 2002-05-16 WO disclosed
WO-2001049654-A2 SUBSTITUTED AMINOMETHYL-PHENYL-CYCLOHEXANE DERIVATIVES Grünenthal GmbH (DE) 2001-07-12 WO disclosed
US-4882048-A POLY(METH)ACRYLAMIDES BONDED TO SILICA GEL; CHROMATOGRAPHIC SEPARATION MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1989-11-21 US disclosed
US-4882048-A POLY(METH)ACRYLAMIDES BONDED TO SILICA GEL; CHROMATOGRAPHIC SEPARATION MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1989-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248979-A1 Method of treating lower urinary tract disorders RYR2, CACNA1S, CACNA1D PTGDR2 168/4885NAAA 292/4885NUDT1 1011/4885
US-20050101590-A1 Cannabinoid receptor agonists CNR1, CNR2, OPRL1 PTGDR2 121/4885NAAA 275/4885NUDT1 2180/4885
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 PTGDR2 144/4885NAAA 3639/4885NUDT1 4182/4885
US-20070105785-A1 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators CACNB2, RYR2, FABP2 PTGDR2 179/4885NAAA 770/4885NUDT1 3039/4885
US-20050203190-A1 Methods of treating gastrointestinal tract disorders using sodium channel modulators SLC10A2, TRPV1, VIPR2 PTGDR2 409/4885NAAA 444/4885NUDT1 2153/4885
US-20050228034-A1 Tetrahydro-indazole cannabinoid modulators CNR2, CNR1, GPR18 PTGDR2 95/4885NAAA 1005/4885NUDT1 3591/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 PTGDR2 92/4885NAAA 206/4885NUDT1 1710/4885
US-20050026835-A1 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators CACNB2, RYR2, FABP2 PTGDR2 179/4885NAAA 770/4885NUDT1 3039/4885
US-20040213842-A1 Methods of treating gastrointestinal tract disorders using sodium channel modulators SLC10A2, VIPR2, TRPV1 PTGDR2 413/4885NAAA 465/4885NUDT1 2275/4885
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 PTGDR2 995/4885NAAA 3558/4885NUDT1 3309/4885
US-20030069288-A1 Substituted aminomethyl-phenyl-cyclohexane derivatives PTGER1, CYP2E1, HRH2 PTGDR2 66/4885NAAA 574/4885NUDT1 1791/4885
US-20050107353-A1 Methods of treating lower urinary tract disorders using losigamone LPXN, TRPM5, SLC10A2 PTGDR2 250/4885NAAA 294/4885NUDT1 654/4885
US-20130303775-A1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL ADH1C, ADH1A, ADH5 PTGDR2 2350/4885NAAA 1362/4885NUDT1 791/4885
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof ADORA2A, ADORA3, ADORA1 PTGDR2 1058/4885NAAA 335/4885NUDT1 26/4885
US-20040209960-A1 Methods of treating lower urinary tract disorders using sodium channell modulators CACNA1G, CACNA1D, CACNA1B PTGDR2 454/4885NAAA 355/4885NUDT1 643/4885
US-20090099143-A1 TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS CNR2, CNR1, GPR18 PTGDR2 95/4885NAAA 1005/4885NUDT1 3591/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 PTGDR2 282/4885NAAA 4340/4885NUDT1 1454/4885
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF ADORA2A, ADORA3, ADORA1 PTGDR2 1058/4885NAAA 335/4885NUDT1 26/4885
US-20050124617-A1 2-Imino-1,3-thiazine derivatives CNR2, CNR1, HTR2C PTGDR2 72/4885NAAA 1213/4885NUDT1 3000/4885
US-20070088020-A1 2-imino-1,3-thiazine derivatives CNR2, CNR1, HTR2C PTGDR2 72/4885NAAA 1213/4885NUDT1 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.